Psychiatric News
Volume 41 Number 15 page 21-21

In an article in the July 7 issue on monitoring adverse effects of antipsychotics, it was noted that Pfizer Inc. is funding a large international study known as the Ziprasidone Observational Study of Cardiac Outcomes. Two details about the study were incorrect.

The study will assess the cardiovascular safety profile of Pfizer's Geodon brand of ziprasidone compared with olanzapine (Eli Lilly's Zyprexa) only, not several other antipsychotics.

The study is being led by Brian Strom, M.D., M.P.H., director of the Center for Clinical Epidemiology and Biostatistics at the University of Pennsylvania School of Medicine, not by John Kane, M.D. Kane is a participating researcher in the study. ▪

Interactive Graphics


Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Articles